J Physiol Society Meetings
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Physiol Vol 437 pp 577-587
Copyright © 1991 by The Physiological Society
This Article
Right arrow Full Text (PDF)
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajakulasingam, K
Right arrow Articles by Howarth, P H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajakulasingam, K
Right arrow Articles by Howarth, P H

Comparative nasal effects of bradykinin, kallidin and [Des-Arg9]-bradykinin in atopic rhinitic and normal volunteers.

K Rajakulasingam, R Polosa, S T Holgate and P H Howarth

Medicine 1, Centre Block, Southampton General Hospital.

1. The structure-activity relationship of kinins within the nose has been investigated in atopic rhinitic (n = 7) and non-rhinitic (n = 7) subjects. On 4 separate days, each separated by a week, subjects randomly underwent nasal challenge with incremental doses of either the B1 agonist [Des-Arg9]-bradykinin, the B2 agonists kallidin or bradykinin, or vehicle placebo in a double-blind comparative study. The nasal response was monitored objectively by measurement of nasal airways resistance (NAR) by active posterior rhinomanometry and subjectively by symptom reporting of nasal blockage, rhinorrhoea, nasal itch and nasal pain. 2. The B2 agonists kallidin and bradykinin both induced a dose-dependent increase in NAR (P less than 0.001) and were associated with symptomatic reporting of nasal blockage (P less than 0.05), rhinorrhoea (P less than 0.01) and nasal discomfort (P less than 0.05) compared to placebo. In contrast the effects of the B1 agonist [Des-Arg9]-bradykinin on NAR and symptom reporting were indistinguishable from placebo. No difference could be identified in the nasal response to kallidin and bradykinin between rhinitic and non-rhinitic subjects and there was no evidence of B1 receptor upregulation in the disease state. For the whole group the provocative dose of agonist inducing a 50% increase in NAR (PD50) was 1.77 x 10(-4) mol for bradykinin and 2.86 x 10(-4) mol for kallidin (P greater than 0.05). 3. These findings identify that the nasal effects of kinins are mediated through B2 receptors and the advent of B2 receptor antagonists will permit a further evaluation of the role of kinins in rhinitis.




This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
M. Schmelz, R. Schmidt, C. Weidner, M. Hilliges, H. E. Torebjork, and H. O. Handwerker
Chemical Response Pattern of Different Classes of C-Nociceptors to Pruritogens and Algogens
J Neurophysiol, May 1, 2003; 89(5): 2441 - 2448.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. J. REYNOLDS, A. TOGIAS, and D. PROUD
Airway Neural Responses to Kinins . Tachyphylaxis and Role of Receptor Subtypes
Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 431 - 438.
[Abstract] [Full Text]


Home page
J. Appl. Physiol.Home page
J. P. Joad, K. S. Kott, and A. C. Bonham
Exposing guinea pigs to ozone for 1 wk enhances responsiveness of rapidly adapting receptors
J Appl Physiol, April 1, 1998; 84(4): 1190 - 1197.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 The Physiological Society.